Article thumbnail

A Volumetric Method for Quantifying Atherosclerosis in Mice by Using MicroCT: Comparison to En Face

By David J. Lloyd, Joan Helmering, Stephen A. Kaufman, James Turk, Matt Silva, Sergio Vasquez, David Weinstein, Brad Johnston, Clarence Hale and Murielle M. Véniant


Precise quantification of atherosclerotic plaque in preclinical models of atherosclerosis requires the volumetric assessment of the lesion(s) while maintaining in situ architecture. Here we use micro-computed tomography (microCT) to detect ex vivo aortic plaque established in three dyslipidemic mouse models of atherosclerosis. All three models lack the low-density lipoprotein receptor (Ldlr−/−), each differing in plaque severity, allowing the evaluation of different plaque volumes using microCT technology. From clearly identified lesions in the thoracic aorta from each model, we were able to determine plaque volume (0.04–3.1 mm3), intimal surface area (0.5–30 mm2), and maximum plaque (intimal-medial) thickness (0.1–0.7 mm). Further, quantification of aortic volume allowed calculation of vessel occlusion by the plaque. To validate microCT for future preclinical studies, we compared microCT data to intimal surface area (by using en face methodology). Both plaque surface area and plaque volume were in excellent correlation between microCT assessment and en face surface area (r2 = 0.99, p<0.0001 and r2 = 0.95, p<0.0001, respectively). MicroCT also identified internal characteristics of the lipid core and fibrous cap, which were confirmed pathologically as Stary type III-V lesions. These data validate the use of microCT technology to provide a more exact empirical measure of ex vivo plaque volume throughout the entire intact aorta in situ for the quantification of atherosclerosis in preclinical models

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). 3D micro-CT imaging of the postmortem brain.
  2. (1994). A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association.
  3. (2007). A dietinduced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.
  4. (1995). A signal processing approach to fair surface design.
  5. (2004). Atherosclerotic lesions at micro CT: feasibility for analysis of coronary artery wall in autopsy specimens.
  6. (2000). Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
  7. (2008). Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob482/2Lepob/ob mice devoid of ApoE or Ldlr.
  8. (2006). Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.
  9. (2009). Images in cardiovascular medicine: Microscopic computed tomography-based virtual histology for visualization and morphometry of atherosclerosis in diabetic apolipoprotein e mutant mice.
  10. (2003). Induction of atherosclerosis by lowfat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement).
  11. (2002). Inflammation in atherosclerosis.
  12. Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis.
  13. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones.
  14. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
  15. (2004). Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer’s disease.
  16. (1994). Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.
  17. (2010). MicroCT-Based Virtual Histology Evaluation of Preclinical Medulloblastoma. Mol Imaging Biol. [Epub ahead of print].
  18. (2000). Natural history and histological classification of atherosclerotic lesions: an update.
  19. (2004). Quantification and 3D reconstruction of atherosclerotic plaque components in apolipoprotein E knockout mice using ex vivo high-resolution MRI.
  20. (2004). Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis.
  21. (1995). Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptordeficient and apolipoprotein E-deficient mice.
  22. (2004). Quantitative analysis of micro-CT imaging and histopathological signatures of experimental arthritis in rats.
  23. (1987). Quantitative assessment of atherosclerotic lesions in mice.
  24. (2002). Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids.
  25. (1997). Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
  26. (2009). The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
  27. (1998). Three-dimensional microcomputed tomography of renal vasculature in rats.
  28. (2001). Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
  29. (2006). Virtual histology of transgenic mouse embryos for high-throughput phenotyping.